EP0190123A1 - Immunoregulierende und antivirale verbindung - Google Patents

Immunoregulierende und antivirale verbindung

Info

Publication number
EP0190123A1
EP0190123A1 EP19840903011 EP84903011A EP0190123A1 EP 0190123 A1 EP0190123 A1 EP 0190123A1 EP 19840903011 EP19840903011 EP 19840903011 EP 84903011 A EP84903011 A EP 84903011A EP 0190123 A1 EP0190123 A1 EP 0190123A1
Authority
EP
European Patent Office
Prior art keywords
cells
compound
mice
virus
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19840903011
Other languages
English (en)
French (fr)
Inventor
Charles O. Gauntt
Kelvin K. Ogilvie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0190123A1 publication Critical patent/EP0190123A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Definitions

  • This invention relates to pharmaceuticals, and more specifically to a compound having anti-viral and immuno regulatory activities.
  • the lymphocyte cells of the mammalian body are of two general groups, namely, T-cells, which are thy ⁇ vus derived and mediate hypersensitivity, and B-cells, which derive from bone marrow and are responsible for antibody production.
  • B-cells invoke an antibody response. They can be further sub-divided into cytotoxic T-lymphocytes, which kill foreign cells, and suppressor T-lymphocytes which modu ⁇ late or suppress the activity of the cytotoxic T-lympho ⁇ cytes.
  • the natural immune system may also involve NK (natu ⁇ ral killer) cells, which are also cytotoxic but are distinct from T-lymphocytes.
  • cytotoxic T-lymphocytes recognize cells as for ⁇ eign, and hence combat them, to an undesirable extent.
  • childhood infections of coxsackievirus can cause heart muscle damage, leading to myocarditis and lesions in the myocardium.
  • the cells lining the blood vessels on the heart muscle cells can become altered, as a consequence of the viral infection.
  • These altered cells are recognized as foreign, by the natural immune system, so that they are combatted by cytotoxic T-lymphocyte and perhaps NK cells, resulting in Dossible destruction of the heart muscle.
  • the rejection of transplated organs by the living body is, of course, commonly caused by the action of the immune system.
  • the present invention provides a substituted guanine compound which exhibits im unoregulatory activity.
  • the compound of the invention has the formula:
  • the compound exerts antimyocarditic activity by immunomodulatory mechanisms which appear to involve T suppressor/T cytotoxic lymphocyte and NK cell subpopulations.
  • the compound has a degree of antiviral activity against coxsackievirus 3, which may or may not be distinct from its immunoregulatory activity.
  • e compoun may e prepare rom -c oroguan ne, a commercially available compound, by reaction with l,3-dibenzyloxy-2-chloromethoxy propane (preparable by reaction of l,3-dibenzyl-2-hydroxy propane and paraformaldehyde with hydrochloric acid) , 6-chloroguanine being suitably protected e.g. with silyl groups.
  • the reagent l,3 7 dibenzyl-2-hydroxy propane can be made by reaction of l,3-dichloro-2-propanol with sodium benzylate.
  • the compound is suitably administered interthecally, from a suitable sterile solution.
  • Effective unit doses for administration are suitably from about 0.1-100 mg of compound per kg mammal body weight, preferably from about 0.1 to about 20 mg per kg, on the basis of a dosage administered 2-4 times per day.
  • Injectable solutions may be made up in distilled water or saline, e.g. isotonic solutions, and optionally buffered with phosphate, of concentration 1000-5000 mg per ml.
  • the drug may be dissolved in dimethyl sulfoxide, diluted in MEM and calf serum, ready for injection.
  • Oral administration as tablets or capsules along with a suitable carrier at the aforementioned approximate dosages, is also within the scope of the present invention.
  • the immunoregulatory activity of the compound was demonstrated by in vivo testing in laboratory mice. Groups of mice infected with coxsackievirus B3 and injected with the com ⁇ pound showed fewer lesions, as compared with similar groups of mice infected with coxsackievirus B3 but not injected with the compound. In_ vitro testing of the compound has shown that it has some antiviral activity, but not sufficient to account for its effects against coasackievirus-induced myocarditic lesions in vivo. Tests conducted on the groups of mice, after sacrifice, have indicated that the compound does not noticeably increase the production of interferons from the cells of mammals-, to account for its activity. In fact, it is found that the administration of the compound has the effect of reducing the number of cytotoxic T-cells whilst stimulating the activity of
  • NK cells and possibly T-suppressor cells are derived from NK cells and possibly T-suppressor cells.
  • the compound is accordingly useful in treatment or alleviation of conditions in living mammals which are adversely affected by the cytotoxic action of cytotoxic T-cells of the mammalian immune system.
  • the acceptance and toleration of coxsackievirus variated cells is an example of such a condition, but the use of the compound of the present invention is not restricted thereto.
  • 6-chloroguanine 200 g, 0.11 moles
  • 1,1,1,3,3,3- hexa ethyldisilazane (HMDS) 200 ml
  • ammonium sulfate 300 mg
  • ED-- n was performed as follows. Duplicate confluent monolayers of cells were challenged with 50-100 pfu of a myocarditic variant of the virus CVB3m (see Gauntt et al, "J.
  • the ED,.,, values calculated for experiments 1-3 respectively were 6, 11 and 7 ug/ml. Based on results from 4 experiments, the ED, was 8.5 — 1.1 ug/ml.
  • the compound was cytotoxic to 25-75% of the cells at 25 ug/ml but was not cytotoxic at a level of 20 ug/ml after 48 hours of incubation. Cells exhibiting cytotoxicity-were rounded up and/or detached. In neonatal mouse skin fibroblasts, toxicity was evidenced by slow growth and elongation of the cells. The drug was toxic to 5-25% of the fibr-oblasts at 15 ug/ml after 48 hours.
  • the fibroblasts used in this and other examples reported herein were prepared and cultured from CD-I or BALB/c neonatal mice born to breeder mice maintained in controlled animal laboratory facilities.'
  • Example 1 The effect of the compound of Example 1 on virus yields in HeLa and neonatal skin fibroblast cultures was assessed in confluent monolayer cultures inoculated with 50 pfu/cell of
  • CVB3m Virus was allowed to absorb for 45-60 minutes and after extensive washing, virus growth medium (MEM containing 1% fetal bovine serum) containing 10,5 or 1 ug/ml of the compound was added to duplicate cultures. After 40 hours incubation at 37°C the cultures were harvested, frozen and thawed three times and the lysates assayed for virus by the plaque ⁇ w.thod. The results are shown in Table II below.
  • the effect of the compound on CVB3-induced myocarditis was examined using male mice.
  • the compound for administration was prepared by dissolving the powder in dimethyl sulfoxide, diluting in MEM with 5% calf serum to 2000 ug/ml and storing at -20°C.
  • Male mice in groups of 3-5 were injected intraperitoneally with 0.16 or 4.0 g/kg body weight of the compound, 2 1/2 - 4 hours prior to virus inoculation. The mice were then inoculated with 10 . or 10 plaque-forming units of
  • Heart tissue from the sacrificed animals was examined for lesions, and assayed for virus. Lesions were counted as described in the aforementioned Gauntt et al paper. Focal area consisting of mononuclear leukocytes and myocytes undergoing necrosis were counted in 2-4 coronal sections per heart, taken one-third the distance from the apex of the heart. Portions of hearts were fixed in phosphate-buffered 10% formalin solution, pH 7.4, the sections were stained with hematoxylin and eosin and examined for lesions.
  • the heart tissues were also assayed for virus.
  • the procedure for disruption of the heart tissues, and other cells, were also assayed for virus.
  • Serum from retroorbital sinus bleedings was assayed for antibody by a standard plaque reduction assay, described by Gauntt et al, "J. Med. Virol.” 3-207-220., 1979.
  • the reciprocal of the dilution at which 90% or greater reduction in plaque number of 1000 plaque-forming units (PFU) of CVB3 occurred was considered the antibody titer.
  • the results of the virus titers on the heart tissues ' showed that the drug did not suppress virus replication _i_n vivo in heart tissues, as titers of virus were either higher than, or not significantly different from, titers in the control group of mice. Again, the group of adult Z mice gave an anomolous result, showing a high virus titer at high drug dose.
  • Sera pooled from mice in four experiments or individually assayed in two experiments for anti-CVB3 neutralizing antibody titers were not significantly different in drug-treated virus-inoculated mice versus virus-inoculated mice
  • VSV vesicular stomatitis virus
  • One unit of interferon reduces plaque formation of 90-120 pfu of
  • VSV by 50%
  • the titer of interferon in a sample is a reciprocal of the dilution of a sample at end point.
  • Interferon titers in sera pooled from 3 mice per sample, determined at 3, 5 and 7 days post injection, were not ⁇ significantly different from control samples, indicating that the antimyocarditic activity of the druq is not attributable to induction of interferon.
  • Flow icrofluorometry was used to determine the proportion of T-cells in splenic lymphocyte populations pooled from BALB/c strain mice, 3-4 animals per group, in the presence and in the absence of the drug.
  • Leukocytes were harvested from spleen by the method described by Gudvanqen et al, "Infect. Immun.”, 41; 1157-1165. (1983) .
  • the splenic lymphocytes were incubated for two one-hour periods at 37°C in complete RPMI 1640 (HEPES buffer at 20mM fetal bovine serum at 10%, gentamycin at 50 ug/ml and 2-mercaptoethanol at 5 x 10 M) to remove adherent cells.
  • the cells were then harvested by centrifugation at 350 x g, washed twice in and taken up in HBSS containing 3% fetal bovine serum and 0.1% sodium nitride to 20 x 10 cell in 1 ml. Fifty icroliters of hybrido a supernatant fluid
  • Lyt2 but not Lytl antigen-positive cells was also found in splenic lymphocytes from drug-treated, CVB3m-inoculated mice. Decreases in proportions of IgM-positive B cells were observed in both virus-inoculated and drug-treated virus-inoculated groups compared to mice in normal or drug-treated groups.
  • CVB3 -inoculated animals with reduced myocarditis have reduced reactivity against infected target cells, when compared with lymphocytes from virus-inoculated controls.
  • An increase in reactivity of T-lymphocyte-depleted splenic cells from drug-treated, CVB3 -inoculated mice suggested the presence of NK cells, as well as data from all three experiments which showed that splenic cells from drug-treated mice had reactivity against infected target cells.
  • NK cells from the four groups were assayed for NK cells reactivity -against YAC-1 cells (obtained from the American type culture collection, Rockville,- Maryland, and cultured in complete RPMI 1640 medium supplemented w ' ith 10% fetal bovine serum, 50 ug/ml gentamycin sulphate, 100 mM sodium piruvate, 2-mercaptoethanol and .-glutamine) .
  • -Cells from mice given the drug and inoculated with CVB3 were slightly higher in
  • the compound also shows a stimulating effect on NK cell activity in CVB3 inoculated mice.
  • An increase in the proportion of splenic T-lymphocytes bearing Thyl and Lyt2 surface markers was effected by the compound of the invention in CVB3 -inoculated animals.
  • the present invention provides a process for alleviating coxsackievirus-induced myocarditis in mammals, which comprises administering to the mammal an effective amount of 6-chloro-9-[[2-benzyloxy-l-(benzyloxymethyl) ethoxy] methyl] guanine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19840903011 1984-07-20 1984-07-20 Immunoregulierende und antivirale verbindung Withdrawn EP0190123A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/001168 WO1986000901A1 (en) 1984-07-20 1984-07-20 Immunoregulatory and anti-viral compound

Publications (1)

Publication Number Publication Date
EP0190123A1 true EP0190123A1 (de) 1986-08-13

Family

ID=22182211

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19840903011 Withdrawn EP0190123A1 (de) 1984-07-20 1984-07-20 Immunoregulierende und antivirale verbindung

Country Status (2)

Country Link
EP (1) EP0190123A1 (de)
WO (1) WO1986000901A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618133D0 (en) * 1986-07-24 1986-09-03 Pa Consulting Services Biosensors
US4876208A (en) * 1987-01-30 1989-10-24 Yellowstone Diagnostics Corporation Diffraction immunoassay apparatus and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4060616A (en) * 1976-03-01 1977-11-29 Burroughs Wellcome Co. Purine derivatives with repeating unit
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
MC1475A1 (fr) * 1981-08-11 1983-06-17 Wellcome Found Procede de preparation de derives de la purine a action anti-virale
US5250535A (en) * 1982-02-01 1993-10-05 Syntex Inc. Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
EP0095813A3 (de) * 1982-06-01 1985-05-08 THE PROCTER & GAMBLE COMPANY Durchdringende topische pharmazeutische Präparate, die 9-(2-Hydroxyäthoxymethyl)-guanin enthalten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8600901A1 *

Also Published As

Publication number Publication date
WO1986000901A1 (en) 1986-02-13

Similar Documents

Publication Publication Date Title
US4795739A (en) Method of inhibiting HIV
Boltz-Nitulescu et al. Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant
Engers et al. Inhibition of T cell-mediated functions by MVM (i), a parvovirus closely related to minute virus of mice.
Chehimi et al. Dendritic cells and IFN-alpha-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood.
Sarkar et al. Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1
JP2004521938A (ja) 腫瘍崩壊性ウイルス治療
US5362490A (en) Human myelomonocyte interferon-gamma, and process for preparation and use thereof
Cabral et al. Δ9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse
FI67848B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara esrar av 9-substituerade hypoxantinderivat
Fleischer et al. Mumps virus replication in human lymphoid cell lines and in peripheral blood lymphocytes: preference for T cells
JPH02502424A (ja) 抗原特異的tセルラインの調製法並びに治療のためのその使用
EP0190123A1 (de) Immunoregulierende und antivirale verbindung
Forghani et al. Association of herpes simplex virus with platelets of experimentally infected mice
De Maeyer et al. Delayed hypersensitivity to Newcastle disease virus in high and low interferon-producing mice.
Raj et al. Cross‐reactive cellular immune responses in chickens vaccinated with live infectious bronchitis virus vaccine
US4529543A (en) Hepatosin
GB2138445A (en) Monoclonal antibody to aspergillus fungi
US5418192A (en) Production of IFN using DA15 peptide
Steele et al. Cellular immune responses to herpesviruses during treatment with adenine arabinoside
AU685162B2 (en) Use of hydroxychloroquine for treatment of graft-versus-host disease
Emery et al. Immune responses of cattle to Theileria parva (East Coast fever): specificity of cytotoxic cells generated in vivo and in vitro.
Gauntt et al. Antimyocarditic activity of the guanine derivative BIOLF-70 in a coxsackievirus B3 murine model
Cantell Towards the clinical use of interferon
Tsuge et al. Comparison of antibody specificities of four anti-thymocyte/anti-lymphocyte globulin products
Saron et al. Beneficial effect of cyclosporin A on the lymphocytic choriomeningitis virus infection in mice

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860624